Isotechnika Pharma signs pact with US FDA on SPA for its lead candidate … – pharmabiz.com
Isotechnika Pharma signs pact with US FDA on SPA for its lead candidate …pharmabiz.comBoth phase III trials will aim to demonstrate non-inferiority in an efficacy endpoint, primarily driven by biopsy proven acute rejection, or BPAR, compared to tacro…